Corporate Compliance

AstraZeneca to pay $520 million for allegedly marketing off-label drug uses

Compliance Monitor, May 5, 2010

Delaware based pharmaceutical giant AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations of illegally marketing the anti-psychotic drug Seroquel for unapproved uses determined by the FDA, according to a Department of Justice (DOJ) press release.

The United States alleges that AstraZeneca illegally marketed Seroquel to psychiatrists and other physicians for a slew of unapproved uses which include treatment for Alzheimer’s, anger management, and dementia. Seroquel is approved to treat forms of schizophrenia and bipolar disorders.

According to the DOJ, AstraZeneca paid doctors to author articles about the unapproved uses of Seroquel, in violation of the anti-kickback statute. The articles were published by AstaZeneca.

James Wetta filed the case under the qui tam provisions of the False Claims Act.  Wetta will receive more than $45 million for his participation.

Most Popular